Vasella to leave Novartis in August


Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company.

He will not seek re-election in February, paving the way for a new chair from 1 August. His successor will be Jörg Reinhardt, who is currently running the drug division at Bayer. Vice chair Ulrich Lehner will serve in the interim.

Vasella was chief executive from 1996 to 2010 and became chair in 1999. His resignation as chief executive in 2010 came after a string of attacks by militant animal rights activists aimed at him and his family. The incoming chair, Reinhardt, is a scientist by training, with a PhD in pharmaceutical sciences, who climbed the R&D ranks at Sandoz before the merger with Ciba-Geigy that created Novartis. He arrives at a challenging time for Novartis, which is struggling with the expiry of patents for many of its financially important drugs.


Related Content

Business roundup

26 February 2010 Business

news image

Industry news, March 2010

US Chemical Safety Board chairman resigns

31 March 2015 News and Analysis

news image

Resignation follows accusation of mismangement and exposure of whistleblowers

Most Read

Chemical linguistics

24 June 2015 Comments

news image

Chemistry is not language, explains Michael Gordin. But the metaphor is useful nonetheless

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...

Most Commented

New and expectant mothers: assessing the risk

24 June 2015 Webinars

news image

Get current, practical and relevant guidance on how to assess the risks and implement control measures for new and expectant ...

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom